Literature DB >> 7745232

Glucagon stimulates GH secretion after intramuscular but not intravenous administration. Evidence against the assumption that glucagon per se has a GH-releasing activity.

E Ghigo1, E Bartolotta, E Imperiale, J Bellone, G Cardinale, G Aimaretti, M R Valetto, V Cherubini, M Maccario, D Cocchi.   

Abstract

In order to verify the true GH-releasing effect of glucagon and to explain the mechanism underlying this effect, we studied the effect of glucagon (GLU, 1 mg) administered either iv or im on both basal and GHRH (1 microgram/kg)-induced GH rise in 48 normal short children and adolescents. Moreover, the in vitro effect of GLU on rat anterior pituitary cells was studied. Intravenous administration of GLU induced no significant GH rise. On the other hand, im GLU administration induced a clear-cut GH increase (mean +/- SE GH peak after GLU vs placebo = 25.7 +/- 3.9 vs 10.1 +/- 3.6 micrograms/L, p < 0.01). Intravenous administration of GLU failed to modify the GHRH-induced GH rise either when coadministered with the neurohormone (35.2 +/- 4.1 vs 34.1 +/- 6.0 micrograms/L) or when given 60 min earlier (20.2 +/- 5.8 vs 21.1 +/- 8.3 micrograms/L). Differently from iv GLU, im GLU strikingly potentiated the GH response to GHRH given 90 min later (57.5 +/- 6.3 vs 24.7 +/- 9.1 micrograms/L, p < 0.01). Mean plasma glucose levels increased 30 min after GLU, administered either iv or im, and returned to basal levels 60 min later. GH secretion from dispersed rat pituitary cells was unaffected by incubation with GLU (10(-10)-10(-4) mol/L). Incubation of the cells with 10(-7) mol/L GHRH induced instead a clear-cut stimulation of GH release. In conclusion, our data demonstrate that glucagon per se has not GH-releasing activity as indicated by its uneffectiveness to release GH in vitro and after intravenous administration.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7745232     DOI: 10.1007/BF03347790

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  19 in total

1.  Effect of exogenous glucagon on pituitary polypeptide hormone release.

Authors:  R L Eddy; A L Jones; R M Hirsch
Journal:  Metabolism       Date:  1970-10       Impact factor: 8.694

2.  Assessment of growth hormone reserve: comparison of intravenous arginina and subcutaneous glucagon stimulation tests.

Authors:  S Podolsky; R Sivaprasad
Journal:  J Clin Endocrinol Metab       Date:  1972-10       Impact factor: 5.958

3.  Hormonal and biochemical response to glucagon administration in patients with pheochromocytoma and in control subjects.

Authors:  G M Cremer; G D Molnar; K E Moxness; S G Sheps; F T Maher; J D Jones
Journal:  Mayo Clin Proc       Date:  1968-03       Impact factor: 7.616

4.  Plasma glucose, non-esterified fatty acid, insulin and growth hormone response to glucagon in the newborn.

Authors:  R D Milner; A D Wright
Journal:  Clin Sci       Date:  1967-04       Impact factor: 6.124

5.  Role of cyclic 3',5'-adenosine monophosphate in the release of growth hormone in vitro.

Authors:  J G Schofield
Journal:  Nature       Date:  1967-09-23       Impact factor: 49.962

6.  Betaxolol and propranolol in glucagon stimulation of growth hormone.

Authors:  M Colle; J Battin; J P Coquelin; P Rochiccioli
Journal:  Arch Dis Child       Date:  1984-07       Impact factor: 3.791

7.  Hypoglycemia: a potent stimulus to secretion of growth hormone.

Authors:  J ROTH; S M GLICK; R S YALOW
Journal:  Science       Date:  1963-05-31       Impact factor: 47.728

8.  Beta-adrenergic stimulation of growth hormone (GH) release in vivo, and subsequent inhibition of GH-releasing factor-induced GH secretion.

Authors:  R J Krieg; S N Perkins; J H Johnson; J P Rogers; A Arimura; M J Cronin
Journal:  Endocrinology       Date:  1988-02       Impact factor: 4.736

9.  Inhibition of hypothalamic somatostatin release by beta-adrenergic antagonists.

Authors:  S B Richardson; S Twente
Journal:  Endocrinology       Date:  1990-02       Impact factor: 4.736

10.  Participation of cholinergic muscarinic receptors in glucagon- and arginine-mediated growth hormone secretion in man.

Authors:  G Delitala; T Frulio; A Pacifico; M Maioli
Journal:  J Clin Endocrinol Metab       Date:  1982-12       Impact factor: 5.958

View more
  7 in total

1.  About the effects of glucagon on growth hormone release.

Authors:  A E Pontiroli
Journal:  J Endocrinol Invest       Date:  1995-05       Impact factor: 4.256

2.  Adding Glucagon-Stimulated GH Testing to the Diagnostic Fast Increases the Detection of GH-Sufficient Children.

Authors:  Colin P Hawkes; Adda Grimberg; Vivian E Dzata; Diva D De Leon
Journal:  Horm Res Paediatr       Date:  2016-03-17       Impact factor: 2.852

3.  Glucagon is an ACTH secretagogue as effective as hCRH after intramuscolar administration while it is ineffective when given intravenously in normal subjects.

Authors:  E Arvat; B Maccagno; J Ramunni; R Giordano; L DiVito; F Broglio; M Maccario; F Camanni; E Ghigo
Journal:  Pituitary       Date:  2000-11       Impact factor: 4.107

4.  Glucagon administration elicits blunted GH but exaggerated ACTH response in obesity.

Authors:  F Tassone; S Grottoli; R Rossetto; B Maccagno; C Gauna; R Giordano; E Ghigo; M Maccario
Journal:  J Endocrinol Invest       Date:  2002-06       Impact factor: 4.256

5.  Hexarelin, a synthetic GH-releasing peptide, is a powerful stimulus of GH secretion in pubertal children and in adults but not in prepubertal children and in elderly subjects.

Authors:  J Bellone; E Bartolotta; C Sgattoni; G Aimaretti; E Arvat; S Bellone; R Deghenghi; E Ghigo
Journal:  J Endocrinol Invest       Date:  1998-09       Impact factor: 4.256

6.  Glucagon stimulation testing in assessing for adult growth hormone deficiency: current status and future perspectives.

Authors:  Kevin C J Yuen
Journal:  ISRN Endocrinol       Date:  2011-08-11

7.  Signal Transduction Mechanisms for Glucagon-Induced Somatolactin Secretion and Gene Expression in Nile Tilapia (Oreochromis niloticus) Pituitary Cells.

Authors:  Chaoyi Zhang; Anji Lian; Yue Xu; Quan Jiang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-04       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.